Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Interferon alpha-2 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 21 Carcinoma, Renal Cell 16 HIV Infections 6 Acquired Immunodeficiency Syndrome 6 Sarcoma, Kaposi 5 Neoplasm Metastasis 4 Lymphoma 4 Leukemia 4 Triple Negative Breast Neoplasms 3 Neoplasms 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Kidney Neoplasms 3 Hematologic Neoplasms 3 Recurrence 2 Pancreatic Neoplasms 2 Mycosis Fungoides 2 Leukemia, Myeloid, Chronic-Phase 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Brain Neoplasms 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Tumor Virus Infections 1 Thrombocythemia, Essential 1 Solid Cancers 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Paclitaxel 3 Carboplatin 2 poly(I).poly(c12,U) 1 pembrolizumab 1 mirabegron 1 liposomal doxorubicin 1 disitamab vedotin 1 apatinib 1 anlotinib 1 Tocotrienols 1 Platinum Compounds 1 Lenalidomide 1 Interferon alpha-2 1 Hyperthermic Intraperitoneal Chemotherapy 1 EP-100 membrane-disrupting peptide 1 Cisplatin 1 Bevacizumab 1 AC 7700 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04072263 2021-04-01

OVACURE

Leiden University Medical Center

Phase 1/2 Unknown

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡